TARIS Biomedical develops new therapies designed for the treatment of difficult-to-treat bladder diseases. The company's system is designed to continuously release drugs in the bladder over weeks to months and is deployed and retrieved using minimally-invasive, in-office procedures, enabling drug release to be tailored to match the needs of each disease.

Indena is the world’s leading company in the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and personal care industries.Indena, a privately owned Italian company, has around 800 employees (10% of them dedicated to full-time research) and has cultivation, manufacturing, and sales in more than 70 countries throughout the world.

TesoRx is a virtual pharmaceutical company developing and commercializing pharmaceutical products. The company engages in developing and commercializing pharmaceutical products. It develops TSX-002, an oral therapeutic testosterone formulation for use in testosterone deficiency in men. The company was incorporated in 2010 and is based in Menlo Park, California.

Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is an American company located in Palo Alto, CA, that develops biopharmaceuticals. Michael Henderson is the current CEO, occupying that position since 2017.\nThe company says this about itself: QED Therapeutics, a subsidiary of BridgeBio Pharma, is a bio technology company focused on precision medicine for FGFR-driven diseases. Our lead investigational candidate is infigratinib, an orally administered FGFR1-3 tyrosine kinase inhibitor that has shown meaningful clinical activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia and other skeletal dysplasias. We plan to conduct further clinical trials to evaluate infigratinib in additional FGFR-driven tumor types and rare disorders.

Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.

Advanced Cardiovascular Systems, Inc. develops and manufactures cardiovascular medical products. It operates as a subsidiary of Abbott Laboratories. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Advanced Cardiovascular Systems, Inc. is based in Santa Clara, California. it is currently known as Abbott Cardiovascular Systems.

Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

LIPAC Oncology is a clinical-stage drug delivery company focused on developing unique localized therapies to treat cancer in challenging parts of the body. It’s breakthrough technology addresses shortcomings of current treatments for Bladder Cancer, Upper Tract Urothelial Carcinoma and Stage II/III Ovarian Cancer.

Verve Medical, Inc. is an early-stage medical device company committed to developing novel, trans- urethral, natural orifice, Renal Denervation devices to ameliorate treatment-resistant hypertension and associated diseases for the benefit of patients world-wide.

United Pharmaceuticals SAS manufactures and distributes pharmaceutical products. The firm specializes in the development of health and nutrition products. The company was founded on January 16, 2004 and is headquartered in Paris, France.

Knight Scientific develops and provides solutions for medical research, sports performance, including horses and camels, natural product testing, pharmaceutical drug development, well-being testing, and diagnostics applications. They offer assays and also test kits for luminometer microplates and tube luminometers.

SCIMED Life Systems is a Manufacturing company.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.

Sichuan Xuhua Pharmaceutical Co., Ltd., established on 1992-07-28, Business scope includes research,to develop,Production,Sales:Granules,tablet,hard capsule,pill(Contains pre-treatment extraction of Chinese herbal medicines),Chinese herbal medicine,Health food sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Sekisui Medical Co., Ltd., part of Sekisui Chemical Co., Ltd., is a company headquartered in Tokyo, Japan, that manufactures and markets in-vitro diagnostic substances and pharmaceutical products. Sekisui Chemical Co., Ltd. acquired Sekisui Medical Co., Ltd. from Daiichi Sankyo Co., Ltd. on October 02, 2006.

Somnics, Inc. engages in the manufacturing, wholesale, and retail of medical devices. It develops technologies and therapy systems for the treatment of Obstructive Sleep Apnea. The company was founded by Chung Chu Chen on March 17, 2010 and is headquartered in Zhubei, Taiwan.

Boston Scientific Ltd., part of Boston Scientific Corp., is a British company located in Hemel Hempstead. The firm distributes medical products. It was founded in 1992.\nThe company says this about itself: Boston Scientific Ltd designed, manufactured and sold transvaginal mesh (“TVM”) medical devices that were implanted into thousands of Canadian women for the treatment of Stress Urinary Incontinence (“SUI”) and Pelvic Organ Prolapse (“POP”).

PharmaGenics, Inc., part of Sanofi, is a company headquartered in Allendale, NJ. The firm develops therapeutic products for cancer. It was founded by Mike I. Sherman. PharmaGenics, Inc. was acquired by Genzyme Corp., now part of Sanofi on June 18, 1997 for $112 million.